Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

P3 Health Partners (PIIIW) Shares Outstanding (Diluted Average) (2022 - 2025)

P3 Health Partners' Shares Outstanding (Diluted Average) history spans 4 years, with the latest figure at $3.3 million for Q4 2025.

  • For Q4 2025, Shares Outstanding (Diluted Average) rose 11.19% year-over-year to $3.3 million; the TTM value through Dec 2025 reached $3.3 million, up 11.19%, while the annual FY2025 figure was $3.3 million, 11.19% up from the prior year.
  • Shares Outstanding (Diluted Average) reached $3.3 million in Q4 2025 per PIIIW's latest filing, roughly flat from $3.3 million in the prior quarter.
  • In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $312.7 million in Q3 2023 to a low of $2.4 million in Q1 2024.
  • Average Shares Outstanding (Diluted Average) over 4 years is $94.7 million, with a median of $22.4 million recorded in 2022.
  • Peak YoY movement for Shares Outstanding (Diluted Average): surged 608.51% in 2023, then plummeted 99.09% in 2024.
  • A 4-year view of Shares Outstanding (Diluted Average) shows it stood at $41.6 million in 2022, then soared by 608.51% to $294.6 million in 2023, then plummeted by 99.0% to $2.9 million in 2024, then rose by 11.19% to $3.3 million in 2025.
  • Per Business Quant, the three most recent readings for PIIIW's Shares Outstanding (Diluted Average) are $3.3 million (Q4 2025), $3.3 million (Q3 2025), and $3.3 million (Q2 2025).